Aficamten clears non-obstructive HCM trial, opening billions

Cytokinetics unveiled May 5 that aficamten (Myqorzo) hit its primary endpoint in ACACIA-HCM, a phase 3 trial in non-obstructive hypertrophic cardiomyopathy. This is territory BMS's Camzyos never entered, opening a multibillion-dollar market. Analysts call it 2026's top cardiovascular catalyst.